CTRI/2023/05/052666
Not yet recruiting
未知
A Study of Individualized Molecular Profiling Guided Therapy Based on Deciphering Recondite Molecular Alterations and Variations in Advanced Solid Tumors - I-DRAV study
Dr. AV Cancer Institute of Personalized Cancer Treatment and Research0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr. AV Cancer Institute of Personalized Cancer Treatment and Research
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male and female patients \>\= 18 years of age, who have agreed to receive either molecularly targeted matched treatment based on molecular profiling analysis or conventional anti\-cancer treatment in routine clinical practice as per their discussion with the treating physician and have provided written informed consent for participation in the study.
- •Patients with incurable malignancies.
- •Patients with cancer of unknown primary, or a rare tumor with no approved therapies.
- •Patients with cancers of hereditary in nature
- •Patients must have the following for a diagnosis/disease status: Relapsed or refractory advanced/metastatic disease, Actionable alterations determined by molecular profiling
- •Molecular profiling (including one or more technologies but not limited to NGS, FISH, IHC, PCR, Microarray, and histopathology) for tumor and/ or blood analysis results should be available with all patients.
- •Known disease status post one or more unmatched systemic therapy regimens.
- •Patients must have a measurable disease for malignancies: defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non\-nodal lesions and short axis for nodal lesions) as \>\=20 mm with conventional techniques or as \>\=10 mm with spiral CT scan, PET\-CT, MRI, or calipers by clinical exam or liquid biopsy showing the ctDNA fraction.
- •ECOG Performance Status 0\-2\.
- •New York Heart Association (NYHA) Functional Classification I\-II.
Exclusion Criteria
- •Severe or uncontrolled medical disorder
- •Pregnant or lactating women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Personalized Molecular Profiling in Cancer Treatment at Johns HopkinsMetastatic Breast CancerNCT02965755Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins200
Recruiting
Not Applicable
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer RecurrencePancreas CancerNCT06228599Medical College of Wisconsin40
Unknown
Not Applicable
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer PatientsAdvanced CancersNCT02160366M.D. Anderson Cancer Center2,000
Recruiting
Not Applicable
Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) ProjectSolid TumorNCT02806388National Cancer Centre, Singapore5,500
Terminated
Not Applicable
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)Hematologic CancerNCT03955276University of California, San Diego13